Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Gains from Investment Securities (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Gains from Investment Securities for 6 consecutive years, with -$10000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 100.1% to -$10000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $15.1 million, a 30.06% increase, with the full-year FY2024 number at $9.3 million, up 13.31% from a year prior.
  • Gains from Investment Securities was -$10000.0 for Q3 2025 at 4D Molecular Therapeutics, down from $2.3 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $10.0 million in Q3 2024 to a low of -$10000.0 in Q3 2025.
  • A 5-year average of $3.5 million and a median of $2.5 million in 2021 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: soared 90778.83% in 2021, then crashed 100.1% in 2025.
  • 4D Molecular Therapeutics' Gains from Investment Securities stood at $480000.0 in 2021, then skyrocketed by 1103.94% to $5.8 million in 2022, then surged by 42.59% to $8.2 million in 2023, then rose by 13.31% to $9.3 million in 2024, then crashed by 100.11% to -$10000.0 in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Gains from Investment Securities are -$10000.0 (Q3 2025), $2.3 million (Q2 2025), and $2.8 million (Q1 2025).